Ionis Pharmaceuticals secured FDA approval for Dawnzera (donidalorsen), a ligand-conjugated antisense therapy designed to prevent attacks in patients with hereditary angioedema (HAE). This marks Ionis' second U.S. FDA approval in under a year. The drug demonstrated an 81% reduction in monthly HAE attack rates versus placebo in a global Phase III trial, with potential dosing intervals extending from four to eight weeks. Ionis aims to position Dawnzera competitively due to its self-administration and dosing flexibility in a market with existing therapies for this rare, life-threatening genetic condition.